Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gamida Cell Ltd (GMDA)

Gamida Cell Ltd (GMDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,037
  • Shares Outstanding, K 154,051
  • Annual Sales, $ 1,780 K
  • Annual Income, $ -63,000 K
  • EBIT $ -73 M
  • EBITDA $ -71 M
  • 60-Month Beta 0.93
  • Price/Sales 3.45
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.63
  • Most Recent Earnings $-0.04 on 03/27/24
  • Next Earnings Date 05/20/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +370,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0303 +7.92%
on 04/01/24
0.4200 -92.21%
on 03/21/24
-0.3273 (-90.92%)
since 03/05/24
3-Month
0.0303 +7.92%
on 04/01/24
0.4870 -93.29%
on 01/29/24
-0.2861 (-89.74%)
since 01/05/24
52-Week
0.0303 +7.92%
on 04/01/24
2.5100 -98.70%
on 06/05/23
-0.7377 (-95.76%)
since 04/05/23

Most Recent Stories

More News
Gamida Cell: Q3 Earnings Snapshot

Gamida Cell: Q3 Earnings Snapshot

GMDA : 0.0327 (-18.25%)
Gamida Cell: Q2 Earnings Snapshot

Gamida Cell: Q2 Earnings Snapshot

GMDA : 0.0327 (-18.25%)
STAND UP TO CANCER NAMES JULIAN ADAMS, Ph.D., CHIEF SCIENCE OFFICER

/PRNewswire/ -- Stand Up To Cancer® (SU2C) today announced that Julian Adams, Ph.D., a longtime oncology researcher and retired pharmaceutical industry chief...

GMDA : 0.0327 (-18.25%)
Gamida Cell: Q1 Earnings Snapshot

Gamida Cell: Q1 Earnings Snapshot

GMDA : 0.0327 (-18.25%)
Gamida Cell Announces Pricing of $23 Million Public Offering of Securities

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the pricing of an underwritten public offering of 17,500,000 ordinary shares and...

GMDA : 0.0327 (-18.25%)
Gamida Cell Announces Launch of Public Offering of Securities

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the launch of a follow-on public offering of its ordinary shares and accompanying...

GMDA : 0.0327 (-18.25%)
Gamida Cell Stock Jumps Over 100% on FDA Approval

Gamida Cell Ltd. (NASDAQ: GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight bloo

PFE : 26.32 (-1.50%)
GMDA : 0.0327 (-18.25%)
GILD : 92.45 (-0.19%)
Gamida Cell (NASDAQ: GMDA) Announces its Omisirge Allogeneic Cell Therapy Receives FDA Approval

Gamida Cell Ltd. (NASDAQ: GMDA) is a biopharma company that is focused on utilizing cell therapy to create innovative therapeutics.

GMDA : 0.0327 (-18.25%)
Promising Upsides on these Biotech Penny Stocks

These three biotech stocks each have a consensus Buy rating. While they are down from historic highs, impressive upsides make them worth consideration.

VTVT : 15.96 (+7.11%)
SABS : 3.62 (+11.04%)
GMDA : 0.0327 (-18.25%)
Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved Gamida Cell’s...

GMDA : 0.0327 (-18.25%)

Business Summary

Gamida Cell Ltd. is a biopharmaceutical company. It focuses on developing cell therapies to cure cancer and rare and serious hematologic diseases. The company's product pipeline consists of NiCord and NAM-NK which are in clinical stage. It operates primarily in the United States, the European Union and...

See More

Key Turning Points

3rd Resistance Point 0.0450
2nd Resistance Point 0.0422
1st Resistance Point 0.0375
Last Price 0.0327
1st Support Level 0.0300
2nd Support Level 0.0272
3rd Support Level 0.0225

See More

52-Week High 2.5100
Fibonacci 61.8% 1.5628
Fibonacci 50% 1.2701
Fibonacci 38.2% 0.9775
Last Price 0.0327
52-Week Low 0.0303

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar